{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:30:45Z","timestamp":1776335445454,"version":"3.51.2"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K01AR051052"],"award-info":[{"award-number":["K01AR051052"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AR061271"],"award-info":[{"award-number":["P30AR061271"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P50AR060780"],"award-info":[{"award-number":["P50AR060780"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0187580","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T17:06:17Z","timestamp":1510247177000},"page":"e0187580","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":68,"title":["Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7964-425X","authenticated-orcid":true,"given":"Viktor","family":"Martyanov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace-Hyun J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bishu J.","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oumar","family":"Sy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Ku","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina S.","family":"Bogatkevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary L.","family":"Schieven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Schiopu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta Gon\u00e7alves","family":"Marangoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Goldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Whitfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Varga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,11,9]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"J Varga","year":"2007","journal-title":"J Clin Invest"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1600-0625.2010.01082.x","article-title":"Scleroderma: from pathophysiology to novel therapeutic approaches","volume":"19","author":"N Hunzelmann","year":"2010","journal-title":"Exp Dermatol"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972\u20132002","volume":"66","author":"VD Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/art.22532","article-title":"Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors","volume":"57","author":"TA McNearney","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/art.38702","article-title":"Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?","volume":"66","author":"EL Herzog","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Y Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nrrheum.2009.26","article-title":"Transforming growth factor beta as a therapeutic target in systemic sclerosis","volume":"5","author":"J Varga","journal-title":"Nat Rev Rheumatol. 2009"},{"issue":"25","key":"ref8","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"SS Baroni","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"ref9","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"CE Daniels","year":"2004","journal-title":"J Clin Invest"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/onc.2008.479","article-title":"A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate","volume":"28","author":"S Bhattacharyya","year":"2009","journal-title":"Oncogene"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12943-015-0468-0","article-title":"Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action","volume":"14","author":"T Bartscht","year":"2015","journal-title":"Mol Cancer"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1586\/1744666X.2013.848792","article-title":"Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development","volume":"9","author":"FV Castelino","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S2213-2600(15)00096-X","article-title":"CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society","volume":"3","author":"DM Hansell","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"A Hochhaus","year":"2008","journal-title":"Leukemia"},{"issue":"24","key":"ref15","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"H Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"ref16","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"NP Shah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","article-title":"Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib","volume":"95","author":"NP Shah","year":"2010","journal-title":"Haematologica"},{"issue":"7","key":"ref18","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1096\/fj.07-105627","article-title":"Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis","volume":"22","author":"A Akhmetshina","year":"2008","journal-title":"FASEB J"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/art.23436","article-title":"Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis","volume":"58","author":"C Skhirtladze","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"e0147005","DOI":"10.1371\/journal.pone.0147005","article-title":"Dasatinib reduces lung inflammation and fibrosis in acute experimental silicosis","volume":"11","author":"FF Cruz","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clim.2008.02.006","article-title":"The Src\/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro","volume":"127","author":"S Blake","year":"2008","journal-title":"Clin Immunol"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation","volume":"111","author":"AE Schade","year":"2008","journal-title":"Blood"},{"issue":"8","key":"ref23","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","article-title":"Profound inhibition of antigen-specific T-cell effector functions by dasatinib","volume":"14","author":"R Weichsel","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"issue":"2","key":"ref25","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"EC LeRoy","year":"1988","journal-title":"J Rheumatol"},{"issue":"7","key":"ref26","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"P Clements","year":"1995","journal-title":"J Rheumatol"},{"issue":"7","key":"ref27","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1124\/dmd.107.018267","article-title":"Metabolism and disposition of dasatinib after oral administration to humans","volume":"36","author":"LJ Christopher","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"ref28","unstructured":"American College of Radiology. CT accreditation program. Testing instructions. Revised January 6, 2017. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.acraccreditation.org\/~\/media\/ACRAccreditation\/Documents\/CT\/CT-Accreditation-Testing-Instructions.pdf?la=en\" xlink:type=\"simple\">http:\/\/www.acraccreditation.org\/~\/media\/ACRAccreditation\/Documents\/CT\/CT-Accreditation-Testing-Instructions.pdf?la=en<\/ext-link>."},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.acra.2009.10.005","article-title":"Reproducibility of lung and lobar volume measurements using computed tomography","volume":"17","author":"MS Brown","year":"2010","journal-title":"Acad Radiol"},{"issue":"5","key":"ref30","first-page":"S26","article-title":"A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients","volume":"28","author":"HG Kim","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"ref31","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.acra.2008.03.011","article-title":"Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study","volume":"15","author":"HJ Kim","year":"2008","journal-title":"Acad Radiol"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2214\/ajr.169.4.9308447","article-title":"Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring","volume":"169","author":"EA Kazerooni","year":"1997","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.09-0108","article-title":"Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study","volume":"136","author":"J Goldin","year":"2009","journal-title":"Chest"},{"issue":"4","key":"ref34","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1093\/nar\/gng015","article-title":"Summaries of Affymetrix GeneChip probe level data","volume":"31","author":"RA Irizarry","year":"2003","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"ref35","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/jid.2013.130","article-title":"Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis","volume":"133","author":"M Hinchcliff","year":"2013","journal-title":"J Invest Dermatol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-015-0669-3","article-title":"Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis","volume":"17","author":"EF Chakravarty","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ng0506-500","article-title":"GenePattern 2.0","volume":"38","author":"M Reich","year":"2006","journal-title":"Nat Genet"},{"issue":"15","key":"ref38","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1093\/bioinformatics\/btl196","article-title":"Comparative gene marker selection suite","volume":"22","author":"J Gould","year":"2006","journal-title":"Bioinformatics"},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"VK Mootha","year":"2003","journal-title":"Nat Genet"},{"issue":"43","key":"ref40","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"A Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"ref41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"A Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00330-011-2223-2","article-title":"Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide","volume":"21","author":"HJ Kim","year":"2011","journal-title":"Eur Radiol"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"R102","DOI":"10.1186\/ar3827","article-title":"Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker?","volume":"14","author":"K Lakota","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"ref44","doi-asserted-by":"crossref","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"A Milano","year":"2008","journal-title":"PLoS One"},{"issue":"5","key":"ref45","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/jid.2011.472","article-title":"Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies","volume":"132","author":"SA Pendergrass","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"e1004005","DOI":"10.1371\/journal.pcbi.1004005","article-title":"Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms","volume":"11","author":"JM Mahoney","year":"2015","journal-title":"PLoS Comput Biol"},{"issue":"W1","key":"ref47","doi-asserted-by":"crossref","first-page":"W83","DOI":"10.1093\/nar\/gkw199","article-title":"g:Profiler-a web server for functional interpretation of gene lists (2016 update)","volume":"44","author":"J Reimand","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"ref48","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1002\/art.39285","article-title":"Editorial: genomic advances in systemic sclerosis: it is time for precision","volume":"67","author":"J Varga","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"ref49","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.bbadis.2012.06.008","article-title":"Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease","volume":"1832","author":"C Beyer","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/B978-0-12-800173-8.00004-0","article-title":"Dasatinib","volume":"39","author":"HM Korashy","year":"2014","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"ref51","unstructured":"Bristol-Myers Squibb. Sprycel\u00ae (dasatinib) highlights of prescribing information. Revised 09\/2016. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf\" xlink:type=\"simple\">http:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf<\/ext-link>."},{"issue":"11","key":"ref52","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"NS Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"ref53","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3899\/jrheum.080633","article-title":"Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma","volume":"36","author":"FN Hant","year":"2009","journal-title":"J Rheumatol"},{"issue":"10","key":"ref54","first-page":"2056","article-title":"Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF","volume":"34","author":"T Matsushita","year":"2007","journal-title":"J Rheumatol"},{"issue":"9","key":"ref55","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00125-012-2598-x","article-title":"Adiponectin: mechanistic insights and clinical implications","volume":"55","author":"AT Turer","year":"2012","journal-title":"Diabetologia"},{"issue":"3","key":"ref56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/JME-12-0003","article-title":"Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion","volume":"48","author":"S Fitter","year":"2012","journal-title":"J Mol Endocrinol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","article-title":"Nilotinib (Tasigna\u2122) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial","volume":"17","author":"JK Gordon","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"ref58","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib","volume":"49","author":"O Hantschel","year":"2008","journal-title":"Leuk Lymphoma"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0187580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T07:31:45Z","timestamp":1540279905000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0187580"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,9]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0187580","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,9]]}}}